Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Disclaimer |

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

submited by

Style Pass

2021-08-15 22:00:05

Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.

Disclaimer | Accessibility Statement | Commerce Policy | Made In NYC | Stock quotes by finanzen.net

HONG KONG , Aug. 9, 2021 /PRNewswire/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between Arvinas' and Insilico Medicine's scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery - PROTACs.

"Arvinas is the pioneer of PROTAC technology and a leader in protein degradation therapeutics. We look forward to collaborating with Arvinas in this innovative field and to building a lasting relationship," said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.